Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID): $1.80

-0.04 (-2.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OVID POWR Grades

  • Sentiment is the dimension where OVID ranks best; there it ranks ahead of 98.24% of US stocks.
  • The strongest trend for OVID is in Growth, which has been heading up over the past 176 days.
  • OVID's current lowest rank is in the Momentum metric (where it is better than 22.16% of US stocks).

OVID Stock Summary

  • OVID THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.11% of US listed stocks.
  • OVID's price/sales ratio is 89.65; that's higher than the P/S ratio of 97.41% of US stocks.
  • Revenue growth over the past 12 months for OVID THERAPEUTICS INC comes in at -99.35%, a number that bests only 0.69% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to OVID, based on their financial statements, market capitalization, and price volatility, are TDUP, NVCN, KOPN, LUMO, and APM.
  • OVID's SEC filings can be seen here. And to visit OVID THERAPEUTICS INC's official web site, go to www.ovidrx.com.

OVID Valuation Summary

  • OVID's price/earnings ratio is -1.9; this is 109.69% lower than that of the median Healthcare stock.
  • OVID's price/earnings ratio has moved up 11.5 over the prior 66 months.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2022-09-23 90.2 0.9 -1.9 -1.0
OVID 2022-09-22 93.6 0.9 -2.0 -1.1
OVID 2022-09-21 93.6 0.9 -2.0 -1.1
OVID 2022-09-20 96.0 0.9 -2.0 -1.2
OVID 2022-09-19 99.9 0.9 -2.1 -1.2
OVID 2022-09-16 101.4 1.0 -2.2 -1.3

OVID's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
  • OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
  • QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.

The table below shows OVID's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.419 1 -10.143
2021-03-31 1.963 1 -8.584
2020-12-31 0.184 1 18.535
2020-09-30 0.099 1 -10.445
2020-06-30 0.000 NA -8.770
2020-03-31 0.000 NA -6.119

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $1.80 52-week high $3.78
Prev. close $1.84 52-week low $1.65
Day low $1.80 Volume 26,600
Day high $1.88 Avg. volume 159,113
50-day MA $2.07 Dividend yield N/A
200-day MA $2.56 Market Cap 126.75M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations sectio

Yahoo | September 27, 2022

10 Best Biotech Stocks Under $10

In this article, we will look at the 10 best biotech stocks under $10. If you want to explore similar biotech stocks with promising prospects that you can get for under $10, you can also take a look at 5 Best Biotech Stocks Under $10. The Global Biotech Industry According to an industry analysis report […]

Yahoo | September 26, 2022

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentati

Yahoo | September 7, 2022

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

The big shareholder groups in Ovid Therapeutics Inc. ( NASDAQ:OVID ) have power over the company. Institutions will...

Yahoo | August 14, 2022

Ladenburg Thalmann & Co. Remains a Buy on Ovid Therapeutics (OVID)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Ovid Therapeutics (OVID - Research Report) today and set a price target of $7.00. The company's shares closed yesterday at $2.18.Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Artelo Biosciences, and BiomX. According to TipRanks, Higgins has an average return of 5.3% and a 30.41% success rate on recommended stocks. Currently, the analyst consensus on Ovid Therapeutics is a Moderate Buy with an average price target of $4.70.

Ryan Adist on TipRanks | August 10, 2022

Read More 'OVID' Stories Here

OVID Price Returns

1-mo -13.04%
3-mo -17.81%
6-mo -44.10%
1-year -49.86%
3-year 47.54%
5-year -57.04%
YTD -43.93%
2021 38.96%
2020 11.33%
2019 71.49%
2018 -75.48%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6069 seconds.